Finance

Lists
000538:SHE
Yunnan Baiyao Group Co Ltd
53,08 CN¥
+0,34%
(+0,18) 1D
16-окт., 15:04:30 GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 000538...
Open
52,89 CN¥
High
53,66 CN¥
Low
52,52 CN¥
Mkt. cap
94,71 млд
Avg. vol.
7,52 млн
Volume
12,92 млн
Dividend
4,94%
Quarterly dividend
0,66 CN¥
Ex-dividend date
2026-ж., 30-апр.
P/E ratio
18,14
52-wk high
58,20 CN¥
52-wk low
46,29 CN¥
EPS
2,93 CN¥
Shares outstanding
1,78 млд
No. of employees
9 миң
Open
52,89 CN¥
High
53,66 CN¥
Low
52,52 CN¥
Mkt. cap
94,71 млд
Avg. vol.
7,52 млн
Volume
12,92 млн
Dividend
4,94%
Quarterly dividend
0,66 CN¥
Ex-dividend date
2026-ж., 30-апр.
P/E ratio
18,14
52-wk high
58,20 CN¥
52-wk low
46,29 CN¥
EPS
2,93 CN¥
Shares outstanding
1,78 млд
No. of employees
9 миң
News stories
From web sources and news partners
Profile
Yunnan Baiyao Group Co., Ltd is a Chinese pharmaceutical company that develops and manufactures pharmaceutical products and the wholesale and retail of pharmaceutical products. The Government Pension Fund of Norway has excluded the company from investments since 21 December 2021, since the company "uses and sells body parts from pangolins which is a globally endangered species". As of 2024, state and individual investors hold 29% of the shares and private companies hold 35%. The three largest shareholders hold 58 per cent of the company's shares. Wikipedia
About Yunnan Baiyao Group Co Ltd
CEO-
Employees9,29 миң
Founded1902
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
9,40 млд
10,53 млд
11,60 млд
10,28 млд
Cost of goods sold
6,70 млд
7,85 млд
8,05 млд
7,28 млд
Cost of revenue
6,70 млд
7,85 млд
8,05 млд
7,28 млд
Research and development expenses
79,10 млн
115,55 млн
76,79 млн
112,78 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,39 млд
2,37 млд
1,28 млд
1,50 млд
Operating expense
1,33 млд
2,67 млд
1,44 млд
1,64 млд
Total operating expenses
8,03 млд
10,52 млд
9,48 млд
8,92 млд
Operating income
1,37 млд
12,79 млн
2,12 млд
1,36 млд
Other non operating income
-43,28 млн
135,88 млн
-17,44 млн
37,87 млн
EBT including unusual items
1,38 млд
428,17 млн
2,36 млд
1,92 млд
EBT excluding unusual items
1,47 млд
233,79 млн
2,35 млд
1,74 млд
Income tax expense
238,66 млн
27,40 млн
330,30 млн
255,01 млн
Effective tax rate
17,25%
6,40%
13,99%
13,27%
Other operating expenses
-18,86 млн
129,96 млн
6,54 млн
116,66 млн
Net income
1,14 млд
376,37 млн
2,04 млд
1,66 млд
Net profit margin
12,18%
3,57%
17,56%
16,18%
Earnings per share
0,61
0,18
1,10
0,87
Interest and investment income
136,98 млн
107,27 млн
253,40 млн
367,65 млн
Interest expense
-4,39 млн
-8,83 млн
-5,09 млн
-5,15 млн
Net interest expenses
132,58 млн
98,43 млн
248,31 млн
362,50 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
1,42 млд
70,91 млн
2,18 млд
1,43 млд
Gain or loss from assets sale
2,26 млн
-8,17 млн
-
-3,05 миң
AI content may include mistakes. Learn more
Google колдонмолору